Review of research leading to new anti-herpesvirus agents in clinical development: Valaciclovir hydrochloride (256u, the L-valyl ester of acyclovir) and 882c, a specific agent for varicella zoster virus

This publication has 12 references indexed in Scilit:

• Amino Acid Ester Prodrugs of Acyclovir
  Antiviral Chemistry and Chemotherapy, 1992
• 6-Methoxypurine arabinoside as a selective and potent inhibitor of varicella-zoster virus
  Antimicrobial Agents and Chemotherapy, 1991
• Analysis of mutations in the thymidine kinase genes of drug-resistant varicella-zoster virus populations using the polymerase chain reaction
  Journal of General Virology, 1991
• A Randomized, Placebo-Controlled Trial of Oral Acyclovir for the Prevention of Cytomegalovirus Disease in Recipients of Renal Allografts
  New England Journal of Medicine, 1989
• A 54-year-old woman with fevers, arthralgias, myalgias, and rash
  The American Journal of Medicine, 1988
• 6-Deoxyacyclovir: a xanthine oxidase-activated prodrug of acyclovir.
  Proceedings of the National Academy of Sciences, 1984
• Pharmacokinetics of acyclovir after intravenous and oral administration
  Journal of Antimicrobial Chemotherapy, 1983
• 5-substituted 2′-deoxyuridines: Correlation between inhibition of tumor cell growth and inhibition of thymidine kinase and thymidylate synthetase
  Biochemical Pharmacology, 1982
• Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine
  Proceedings of the National Academy of Sciences, 1977
• A virus-specific thymidine kinase in BHK21 cells infected with herpes simplex virus
  Virology, 1967